{"DataElement":{"publicId":"3553272","version":"1","preferredName":"Tumor Immune Response Type","preferredDefinition":"Text term representing the response to treatment of a tumor/disease based on Immune-Related Response Criteria (irRC).","longName":"TUM_IMM_RESP_TP","context":"NCI Standards","contextVersion":"1","DataElementConcept":{"publicId":"3553262","version":"1","preferredName":"Tumor Immune Response","preferredDefinition":"the response to treatment of the tumor/disease.__Response; a bodily process occurring due to the effect of some foregoing stimulus or agent._Protected against infectious disease by either specific or non-specific mechanisms. (On-line Medical Dictionary)","longName":"TUM_IMM_RESP","context":"NCI Standards","contextVersion":"1","ObjectClass":{"publicId":"2404687","version":"1","preferredName":"Neoplasm","preferredDefinition":"(NEE-o-PLAY-zha) Abnormal and uncontrolled cell growth.","longName":"C3262","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Neoplasm","conceptCode":"C3262","definition":"A benign or malignant tissue growth resulting from uncontrolled cell proliferation. Benign neoplastic cells resemble normal cells without exhibiting significant cytologic atypia, while malignant cells exhibit overt signs such as dysplastic features, atypical mitotic figures, necrosis, nuclear pleomorphism, and anaplasia. Representative examples of benign neoplasms include papillomas, cystadenomas, and lipomas; malignant neoplasms include carcinomas, sarcomas, lymphomas, and leukemias.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Application","id":"0094ACAF-11BC-1BCA-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-09-12","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2005-09-12","modifiedBy":"ONEDATA","dateModified":"2005-09-12","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"Property":{"publicId":"3153138","version":"1","preferredName":"Immune Response","preferredDefinition":"Protected against infectious disease by either specific or non-specific mechanisms. (On-line Medical Dictionary):Response; a bodily process occurring due to the effect of some foregoing stimulus or agent.","longName":"C17997:C25755","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Immune","conceptCode":"C17997","definition":"Protected against infectious disease by either specific or non-specific mechanisms.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Response","conceptCode":"C25755","definition":"Any act or phenomena, or behavior, constituting a reply or reaction of a living organism or its part to some foregoing stimulus or agent.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"93A3CEB3-65D5-7DC3-E040-BB89AD4361AE","latestVersionIndicator":"Yes","beginDate":"2010-10-27","endDate":null,"createdBy":"PANH","dateCreated":"2010-10-27","modifiedBy":"ONEDATA","dateModified":"2010-10-27","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ConceptualDomain":{"publicId":"2008550","version":"1","preferredName":"Disease Response","preferredDefinition":"the response criteria (includes RECIST and others) and associated documentation of disease.","longName":"DZ_RESP","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B22C0651-216B-5273-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-19","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-19","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Qualified","id":"C6C01A2E-43AD-5529-E040-BB89AD434A72","latestVersionIndicator":"Yes","beginDate":"2012-08-08","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-08-08","modifiedBy":"KNABLEJ","dateModified":"2017-08-23","changeDescription":"8/23/17 jk transferred context and added CSI, registration status per Round 5 finalization task","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ValueDomain":{"publicId":"3553264","version":"1","preferredName":"Immune Response Type","preferredDefinition":"1. any response of the immune system to an antigen including antibody production and/or cell-mediated immunity; 2. the response of the immune system to an antigen (immunogen) that leads to the condition of induced sensitivity; the immune response to the initial antigenic exposure (primary immune response) is detectable, as a rule, only after a lag period of from several days to two weeks; the immune response to a subsequent stimulus (secondary immune response) by the same antigen is more rapid than in the case of the primary immune response._Something distinguishable as an identifiable class based on common qualities.","longName":"IMM_RESP_TP","context":"CCR","contextVersion":"1","type":"Enumerated","dataType":"CHARACTER","minLength":null,"maxLength":"50","minValue":null,"maxValue":null,"decimalPlace":null,"PermissibleValues":[{"value":"irPD","valueDescription":"Immune-related Progressive Disease","ValueMeaning":{"publicId":"3553265","version":"1","preferredName":"Immune-related Progressive Disease","longName":"3553265v1.00","preferredDefinition":"Increase in tumor burden greater than or equal to 25 percent relative to nadir (minimum recorded tumor burden); confirmation by a repeat, consecutive assessment no less than 4 weeks from the date first documented.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Immune-Related Response Criteria Progressive Disease","conceptCode":"C148196","definition":"Increase in tumor burden greater than or equal to 25 percent relative to nadir (minimum recorded tumor burden); confirmation by a repeat, consecutive assessment no less than 4 weeks from the date first documented.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"C6C01A2E-43E5-5529-E040-BB89AD434A72","latestVersionIndicator":"Yes","beginDate":"2012-08-08","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-08-08","modifiedBy":"CLOHNES","dateModified":"2023-07-06","changeDescription":null,"administrativeNotes":"7/6/23 Added missing concept per cleanup activities cjl.","unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"C6C01A2E-43FE-5529-E040-BB89AD434A72","beginDate":"2012-08-08","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-08-08","modifiedBy":"ONEDATA","dateModified":"2012-08-08","deletedIndicator":"No"},{"value":"irSD","valueDescription":"Immune-related Stable Disease","ValueMeaning":{"publicId":"3553266","version":"1","preferredName":"Immune-related Stable Disease","longName":"3553266v1.00","preferredDefinition":"Not meeting criteria for irCR or irPR, in absence of irPD.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Immune-Related Response Criteria Stable Disease","conceptCode":"C148195","definition":"Not meeting criteria for irCR or irPR, in absence of irPD.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"C6C01A2E-4408-5529-E040-BB89AD434A72","latestVersionIndicator":"Yes","beginDate":"2012-08-08","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-08-08","modifiedBy":"CLOHNES","dateModified":"2023-07-07","changeDescription":null,"administrativeNotes":"7/7/23 Added missing concept per cleanup activities cjl.","unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"C6C01A2E-4421-5529-E040-BB89AD434A72","beginDate":"2012-08-08","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-08-08","modifiedBy":"ONEDATA","dateModified":"2012-08-08","deletedIndicator":"No"},{"value":"irPR","valueDescription":"Immune-related Partial Response","ValueMeaning":{"publicId":"3553267","version":"1","preferredName":"Immune-related Partial Response","longName":"3553267v1.00","preferredDefinition":"Decrease in tumor burden greater than or equal to 50 percent relative to baseline confirmed by a consecutive assessment at least 4 weeks after first documentation.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Immune-Related Response Criteria Partial Response","conceptCode":"C148194","definition":"Decrease in tumor burden greater than or equal to 50 percent relative to baseline confirmed by a consecutive assessment at least 4 weeks after first documentation.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"C6C01A2E-442B-5529-E040-BB89AD434A72","latestVersionIndicator":"Yes","beginDate":"2012-08-08","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-08-08","modifiedBy":"CLOHNES","dateModified":"2023-07-06","changeDescription":null,"administrativeNotes":"7/6/23 Added missing concept per cleanup actiivities cjl.","unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"C6C01A2E-4444-5529-E040-BB89AD434A72","beginDate":"2012-08-08","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-08-08","modifiedBy":"ONEDATA","dateModified":"2012-08-08","deletedIndicator":"No"},{"value":"irCR","valueDescription":"Immune-related Complete Response","ValueMeaning":{"publicId":"3553268","version":"1","preferredName":"Immune-related Complete Response","longName":"3553268v1.00","preferredDefinition":"Complete disappearance of all lesions (whether measurable or not, and no new lesions); confirmation by a repeat, consecutive assessment no less than 4 weeks from the date first documented.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Immune-Related Response Criteria Complete Response","conceptCode":"C148193","definition":"Complete disappearance of all lesions (whether measurable or not, and no new lesions); confirmation by a repeat, consecutive assessment no less than 4 weeks from the date first documented.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"C6C01A2E-444E-5529-E040-BB89AD434A72","latestVersionIndicator":"Yes","beginDate":"2012-08-08","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-08-08","modifiedBy":"CLOHNES","dateModified":"2023-07-06","changeDescription":null,"administrativeNotes":"7/6/23 Added missing concept per cleanup activities cjl.","unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"C6C01A2E-4467-5529-E040-BB89AD434A72","beginDate":"2012-08-08","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-08-08","modifiedBy":"ONEDATA","dateModified":"2012-08-08","deletedIndicator":"No"},{"value":"Non-index lesions","valueDescription":"Non-index lesions","ValueMeaning":{"publicId":"3553269","version":"1","preferredName":"Non-index lesions","longName":"3553269v1.00","preferredDefinition":"Any tumor lesion other than the largest tumor lesion targeted by therapy.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Non-Index Lesion","conceptCode":"C110962","definition":"Any tumor lesion other than the largest tumor lesion targeted by therapy.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"C6C01A2E-4471-5529-E040-BB89AD434A72","latestVersionIndicator":"Yes","beginDate":"2012-08-08","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-08-08","modifiedBy":"CLOHNES","dateModified":"2023-07-07","changeDescription":null,"administrativeNotes":"7/7/23 Added missing concept per cleaning activities cjl.","unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"C6C01A2E-448A-5529-E040-BB89AD434A72","beginDate":"2012-08-08","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-08-08","modifiedBy":"ONEDATA","dateModified":"2012-08-08","deletedIndicator":"No"},{"value":"New, nonmeasurable lesions (<5x5 mm)","valueDescription":"New nonmeasurable lesions (< 5x5 mm)","ValueMeaning":{"publicId":"3553270","version":"1","preferredName":"New nonmeasurable lesions (< 5x5 mm)","longName":"3553270","preferredDefinition":"Do not define progression (but preclude irCR)","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"C6C01A2E-4494-5529-E040-BB89AD434A72","latestVersionIndicator":"Yes","beginDate":"2012-08-08","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-08-08","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"C6C01A2E-44AD-5529-E040-BB89AD434A72","beginDate":"2012-08-08","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-08-08","modifiedBy":"ONEDATA","dateModified":"2012-08-08","deletedIndicator":"No"},{"value":"New, measurable lesions (>=5x5 mm)","valueDescription":"New measurable lesions (>= 5x5 mm)","ValueMeaning":{"publicId":"3553271","version":"1","preferredName":"New measurable lesions (>= 5x5 mm)","longName":"3553271","preferredDefinition":"Incorporated into tumor burden","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"C6C01A2E-44B7-5529-E040-BB89AD434A72","latestVersionIndicator":"Yes","beginDate":"2012-08-08","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-08-08","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"C6C01A2E-44D0-5529-E040-BB89AD434A72","beginDate":"2012-08-08","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-08-08","modifiedBy":"ONEDATA","dateModified":"2012-08-08","deletedIndicator":"No"},{"value":"Not Evaluable","valueDescription":"Not Assessable/Not Evaluable","ValueMeaning":{"publicId":"3361719","version":"1","preferredName":"Not Assessable/Not Evaluable","longName":"3361719","preferredDefinition":"Unable to be evaluated.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Unevaluable","conceptCode":"C62222","definition":"Unable to be evaluated.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B736A379-719C-37F3-E040-BB89AD4345C4","latestVersionIndicator":"Yes","beginDate":"2012-01-23","endDate":null,"createdBy":"ALAIS","dateCreated":"2012-01-23","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"E4EF44DE-DBF6-4C6C-E040-BB89AD435952","beginDate":"2013-08-27","endDate":null,"createdBy":"COOPERM","dateCreated":"2013-08-27","modifiedBy":"ONEDATA","dateModified":"2013-08-27","deletedIndicator":"No"}],"ConceptualDomain":{"publicId":"2008563","version":"1","preferredName":"Therapy Results","preferredDefinition":"the results or effects (does not include CTC Adverse Events) of therapeutic agents or procedures administered to the patient.","longName":"TX_RESULTS","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B6690D31-4081-494A-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2003-01-06","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2003-02-11","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"RepresentationTerm":{"publicId":"3553263","version":"1","preferredName":"Immune Response Type","preferredDefinition":"1. any response of the immune system to an antigen including antibody production and/or cell-mediated immunity; 2. the response of the immune system to an antigen (immunogen) that leads to the condition of induced sensitivity; the immune response to the initial antigenic exposure (primary immune response) is detectable, as a rule, only after a lag period of from several days to two weeks; the immune response to a subsequent stimulus (secondary immune response) by the same antigen is more rapid than in the case of the primary immune response.:Something distinguishable as an identifiable class based on common qualities.","longName":"C17930:C25284","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Immune Response Process","conceptCode":"C17930","definition":"Any immune system response of an organisms to an internal or invasive threat.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Type","conceptCode":"C25284","definition":"Something distinguishable as an identifiable class based on common qualities.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"C6C01A2E-43C1-5529-E040-BB89AD434A72","latestVersionIndicator":"Yes","beginDate":"2012-08-08","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-08-08","modifiedBy":"ONEDATA","dateModified":"2012-08-08","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"C6C01A2E-43D2-5529-E040-BB89AD434A72","latestVersionIndicator":"Yes","beginDate":"2012-08-08","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-08-08","modifiedBy":"KNABLEJ","dateModified":"2017-08-23","changeDescription":"8/23/17 jk used in Standard CDE; added Application reg status and CSI per Round 5 finalization task.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ClassificationSchemes":[{"publicId":"2008601","version":"1","longName":"C3D Domain","context":"CCR","ClassificationSchemeItems":[{"publicId":"2811685","version":"1","longName":"CCR","context":"CCR"}]},{"publicId":"2182125","version":"1","longName":"CCR Implementation","context":"CCR","ClassificationSchemeItems":[{"publicId":"2811673","version":"1","longName":"C3D","context":"CCR"}]},{"publicId":"2192345","version":"1","longName":"Data Standards","context":"NCIP","ClassificationSchemeItems":[{"publicId":"2859963","version":"1","longName":"Standard CRFs","context":"NCIP"},{"publicId":"3813676","version":"1","longName":"Response CRF","context":"NCIP"}]},{"publicId":"5635300","version":"1","longName":"Case Report Form (CRF) Modules","context":"NCI Standards","ClassificationSchemeItems":[{"publicId":"3813675","version":"1","longName":"Response","context":"NCI Standards"}]}],"AlternateNames":[{"name":"caBIG","type":"USED_BY","context":"NCIP"},{"name":"ECOG-ACRIN","type":"USED_BY","context":"ECOG-ACRIN"},{"name":"Theradex","type":"USED_BY","context":"Theradex"}],"ReferenceDocuments":[{"name":"irRC response","type":"Preferred Question Text","description":"irRC response","url":null,"context":"NCI Standards"},{"name":"ECOG CRF Text 1","type":"Alternate Question Text","description":"Response of Target lesions","url":null,"context":"ECOG-ACRIN"},{"name":"ECOG CRF Text 2","type":"Alternate Question Text","description":"Response of Non-Target lesions","url":null,"context":"ECOG-ACRIN"},{"name":"ECOG CRF Text 3","type":"Alternate Question Text","description":"Overall Response","url":null,"context":"ECOG-ACRIN"},{"name":"Theradex - 1","type":"Alternate Question Text","description":"Immune Response (irRC).","url":null,"context":"Theradex"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Standard","id":"C6C01A2E-44DA-5529-E040-BB89AD434A72","latestVersionIndicator":"Yes","beginDate":"2012-08-08","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-08-08","modifiedBy":"CLOHNES","dateModified":"2023-07-06","changeDescription":"8/23/17 jk transferred context and added registration status per Round 5 finalization task.  --- Curated to support NCI CCR clinical trial","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"}}